In response to a report printed on December 11, 2025, by The Washington Publish, President Donald Trump is contemplating an government order that may direct federal businesses to reclassify marijuana from Schedule I to Schedule III underneath the Managed Substances Act. This potential shift, which might happen as early as Monday, December 15, would signify a major federal coverage adjustment, easing sure restrictions whereas sustaining prohibitions on non-medical use. Nevertheless, a White Home official acknowledged that no remaining selections have been made, in line with Forbes.
The event follows discussions within the Oval Workplace involving hashish business executives, throughout which Trump consulted Home Speaker Mike Johnson, who expressed reservations, sources advised The Washington Publish. CNBC reported on December 12 {that a} supply acquainted with the matter indicated the order might be signed early the next week.
Financial and Analysis Implications
Rescheduling would align marijuana with substances comparable to ketamine and sure codeine mixtures, acknowledging accepted medical functions and decrease abuse potential in comparison with Schedule I medication. A companion evaluation by The Washington Publish on December 12 outlined potential shopper impacts, together with expanded analysis and doable Medicare protection for sure cannabidiol therapies.
For the hashish business, estimated at over $32 billion, the first profit would contain alleviation of Inner Income Code Part 280E restrictions, which at the moment forestall deductions of bizarre enterprise bills and lead to efficient tax charges reaching 80%.
Brian Vicente, founding associate at Vicente LLP, described the prospect: “This monumental change can have a large, optimistic impact on 1000’s of state-legal hashish companies across the nation. One dominating inequity hashish companies face is the shortcoming to deduct common enterprise bills, since they promote a Schedule I substance. Rescheduling releases hashish companies from the crippling tax burden they’ve been shackled with and permit these companies to develop and prosper.”
Ryan Hunter, chief income officer at Spherex, famous parallels with present pharmaceuticals: “By shifting hashish to Schedule 3, Hashish might be handled equally to ketamine, Tylenol + Codeine, and anabolic steroids—all medication which were accredited by the FDA to be used with a physician’s prescription.” He instructed this might improve affected person entry in non-medical states and prioritize therapeutic merchandise.
Trade Views
Advocates throughout the sector voiced measured help. Jim Belushi, founding father of Belushi’s Farm, exclaimed: “ABOUT TIME!!!” Mark Lewis, president of specialty banking at Lüt, known as it probably “the one most essential drug coverage transfer in many years,” citing alternatives for analysis and entry, although he famous ongoing challenges absent measures just like the SAFE Banking Act.
Jasmine Johnson, CEO of GŪD Essence, emphasised preparedness: “A reclassification would assist speed up scientific analysis, develop entry for sufferers, and scale back pointless obstacles for regulated operators who’re doing the work the proper manner.”
But coherence issues persist amid current hemp product restrictions. Tamara Anderson, founding father of Culinary & Hashish, questioned timing: “Everybody retains asking why this, why now? The reality is, we’d like rescheduling, however we’d like it achieved responsibly. One minute the administration is speaking about recalling hemp merchandise, the following they’re floating a reschedule.”
Tyler Cartwright, co-founder and chief working officer at Larger Requirements, highlighted inconsistencies: “We’re now taking a look at a possible future the place marijuana, which stays federally prohibited, will get rescheduled primarily based on its medical advantages, whereas hemp-derived wellness merchandise which were authorized and controlled underneath the 2018 Farm Invoice for seven years get shut down. That’s not coherent coverage.”
Skepticism and Potential Hurdles
Critics raised alarms over pharmaceutical dominance and regulatory shifts. Josh Kesselman, writer of Excessive Occasions Journal and founding father of RAW Rolling Papers, warned of a “false flag,” asserting it might allow huge pharma to market artificial THC prescriptions whereas imposing new federal violations on dispensaries underneath the Meals, Drug, and Beauty Act.
Jeffrey Miller, chief government officer of HoneyProjects, welcomed tax reduction however urged warning: “Any loosening of federal hashish coverage deserves acknowledgment, however a transfer to Schedule III introduces actual uncertainty for small companies in state-regulated markets.”
Harrison Bard, CEO and co-founder of Customized Cones USA and DaySavers, noticed advantages for veterans however dangers for independents. Alex Gonzalez, president and co-founder of Calyx Containers, anticipated stricter requirements: “Each time the White Home strikes ahead with Schedule III, the federal authorities is successfully telling us that hashish is drugs. And if it’s drugs, ‘adequate’ hashish practices received’t minimize it anymore.”
Sierra Elaina, CEO of Lehua Manufacturers, regarded it as overdue legitimacy, whereas Gennaro Luce, founder and CEO of CannaLnx, harassed insurance coverage frameworks for affordability. Sasha Nutgent, vice chairman of hashish retail at Housing Works Hashish Co., anticipated incentives for authorized operations, notably amongst justice-impacted house owners.
Inner resistance contains figures like DEA Administrator Terrance Cole, who has not prioritized rescheduling, and potential authorized challenges from teams comparable to Sensible Approaches to Marijuana, as famous in earlier protection.
Reuters reported on December 12 that hashish shares surged following the preliminary disclosures, reflecting market anticipation. Ought to the directive advance, it will construct on a stalled Biden-era assessment, marking pragmatic alignment with scientific assessments and state insurance policies in 40 jurisdictions, although leaving broader federal-state conflicts unresolved.
